Episodes

  • Advancing Pharmacist Engagement in Biliary Tract Cancer: Disease State and Treatment Considerations

    Advancing Pharmacist Engagement in Biliary Tract Cancer: Disease State and Treatment Considerations
    Jul 1 2025
    Courtney Cavalieri, PharmD, BCOP, and Kenneth Tham, PharmD, BCOP, discuss how pharmacists play a crucial role in managing biliary tract cancer patients by providing expertise on biomarker testing, treatment selection between targeted therapies like FGFR and HER2 inhibitors, developing monitoring protocols for unique toxicities such as hyperphosphatemia, and educating patients on side effect management to optimize treatment outcomes in this rare cancer type.
    Show more Show less
    32 mins
  • Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer

    Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
    Jun 5 2025
    Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic castration-resistant prostate cancer (nmCRPC) show darolutamide may offer superior tolerability with lower discontinuation rates and fewer drug interactions, while emphasizing the importance of critically evaluating real-world studies by examining methodology rather than just conclusions.
    Show more Show less
    32 mins
  • Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME

    Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME
    May 28 2025
    Ehsan Rahimy, MD; David G. Miller, MD, Michael Klufas, MD, discusses how real-world treatment strategies for neovascular AMD and DME with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.
    Show more Show less
    37 mins
  • Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases

    Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases
    May 28 2025
    Ehsan Rahimy, MD; David G. Miller, MD, Esther Kim, MD, discusses how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases like AMD and DME, while highlighting the benefits of newer agents like aflibercept 8mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.
    Show more Show less
    35 mins
  • Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME

    Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME
    May 28 2025
    Ehsan Rahimy, MD; David G. Miller, MD, Michael Klufas, MD, discusses how real-world treatment strategies for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.
    Show more Show less
    37 mins
  • Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases

    Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases
    May 28 2025
    35 mins
  • Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies

    Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies
    Apr 11 2025
    Ehsan Rahimy, MD; David G. Miller, MD; and Esther Kim, MD, discuss how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases such as age-related macular degeneration and diabetic macular edema while highlighting the benefits of newer agents such as aflibercept 8 mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.
    Show more Show less
    32 mins
  • Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment

    Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
    Apr 1 2025
    Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival out
    Show more Show less
    46 mins